{"id":"cefpimizole","rwe":[{"pmid":"36209969","year":"2022","title":"Co-infections of Aeromonas veronii and Nocardia seriolae in largemouth bass (Micropterus salmoides).","finding":"","journal":"Microbial pathogenesis","studyType":"Clinical Study"},{"pmid":"9603632","year":"1998","title":"Immunopharmacology of oral betalactams.","finding":"","journal":"Journal of chemotherapy (Florence, Italy)","studyType":"Clinical Study"},{"pmid":"8690304","year":"1996","title":"[Nephrotoxicity and drug interaction of vancomycin (2)].","finding":"","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica","studyType":"Clinical Study"},{"pmid":"8999285","year":"1996","title":"Reduced anti-Pseudomonas aeruginosa activity of a cephalosporin, cefodizime, in rats whose neutrophils were selectively depleted by a monoclonal antibody.","finding":"","journal":"Microbiology and immunology","studyType":"Clinical Study"},{"pmid":"1324894","year":"1992","title":"Upregulatory effects of cefpimizole natrium on human leukocytes.","finding":"","journal":"International journal of immunopharmacology","studyType":"Clinical Study"}],"tags":[{"label":"cefpimizole","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cefpimizol","offLabel":[],"synonyms":["cefpimizole sodium","cefpimizol","cefpimizole disodium","cefpimizole"],"timeline":[],"brandName":"Cefpimizol","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cefpimizole","explanation":"Imagine your body's cells are like buildings, and the bacteria are like construction workers. Cefpimizole stops the construction workers from building new walls, which eventually causes the building to collapse and die. This is how cefpimizole fights bacterial infections.","oneSentence":"Cefpimizole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"Cefpimizole exerts its antibacterial effects by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thereby inhibiting the transpeptidation reaction that is essential for bacterial cell wall synthesis and ultimately leading to bacterial cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3075","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFPIMIZOLE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:16:29.531635","biosimilars":[],"competitors":[],"genericName":"cefpimizole","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"24S58UHU7N","CHEBI":"CHEBI:31376","INN_ID":"5464","UMLSCUI":"C0055009","ChEMBL_ID":"CHEMBL2103902","KEGG_DRUG":"D01568","PUBCHEM_CID":"68597","IUPHAR_LIGAND_ID":"10779","SECONDARY_CAS_RN":"85287-61-2","MESH_SUPPLEMENTAL_RECORD_UI":"C038845"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.8 hours","clearance":"1.7 mL/min/kg","volumeOfDistribution":"0.21 L/kg"},"publicationCount":39,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2022 Dec","pmid":"36209969","title":"Co-infections of Aeromonas veronii and Nocardia seriolae in largemouth bass (Micropterus salmoides).","journal":"Microbial pathogenesis"},{"date":"1998 Apr","pmid":"9603632","title":"Immunopharmacology of oral betalactams.","journal":"Journal of chemotherapy (Florence, Italy)"},{"date":"1996 May","pmid":"8690304","title":"[Nephrotoxicity and drug interaction of vancomycin (2)].","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica"},{"date":"1996","pmid":"8999285","title":"Reduced anti-Pseudomonas aeruginosa activity of a cephalosporin, cefodizime, in rats whose neutrophils were selectively depleted by a monoclonal antibody.","journal":"Microbiology and immunology"},{"date":"1992 Jul","pmid":"1324894","title":"Upregulatory effects of cefpimizole natrium on human leukocytes.","journal":"International journal of immunopharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefpimizole is a small molecule antibiotic in the cefpimizole class, but its target and approved indications are unknown. Its half-life is approximately 1.8 hours. The commercial status of cefpimizole is unclear, and it is not known whether it is patented or available as a generic medication. Further information on its development, approval, and safety profile is needed. As a result, cefpimizole is not widely recognized or used in clinical practice.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}